158
Views
12
CrossRef citations to date
0
Altmetric
Original Research

Hypomagnesemia in diabetes patients: comparison of serum and intracellular measurement of responses to magnesium supplementation and its role in inflammation

, , , &
Pages 389-400 | Published online: 02 Aug 2018

References

  • Barbagallo M Di Bella G Brucato V Serum ionized magnesium in diabetic older persons Metabolism 2014 63 4 502 509 24462317
  • Rodriguez-Moran M Simental Mendia LE Zambrano Galvan G Guerrero-Romero F The role of magnesium in type 2 diabetes: a brief based-clinical review Magnes Res 2011 24 4 156 162 22198525
  • Kao WH Folsom AR Nieto FJ Mo JP Watson RL Brancati FL Serum and dietary magnesium and the risk for type 2 diabetes mellitus: the Atherosclerosis Risk in Communities Study Arch Intern Med 1999 159 18 2151 2159 10527292
  • Rude RK Magnesium deficiency and diabetes mellitus. Causes and effects Postgrad Med 1992 92 5 217 219 222 224
  • Silver BB Development of cellular magnesium nano-analysis in treatment of clinical magnesium deficiency J Am Coll Nutr 2004 23 6 732S 737S 15637223
  • Haigney MC Silver B Tanglao E Noninvasive measurement of tissue magnesium and correlation with cardiac levels Circulation 1995 92 8 2190 2197 7554201
  • Simental-Mendia LE Rodriguez-Moran M Guerrero-Romero F Oral magnesium supplementation decreases C-reactive protein levels in subjects with prediabetes and hypomagnesemia: a clinical randomized double-blind placebo-controlled trial Arch Med Res 2014 45 4 325 330 24814039
  • Seidell JC Flegal KM Assessing obesity: classification and epidemiology Br Med Bull 1997 53 2 238 252 9246834
  • Guerrero-Romero F Rodriguez-Moran M Magnesium improves the beta-cell function to compensate variation of insulin sensitivity: double-blind, randomized clinical trial Eur J Clin Invest 2011 41 4 405 410 21241290
  • Tosiello L Hypomagnesemia and diabetes mellitus. A review of clinical implications Arch Intern Med 1996 156 11 1143 1148 8639008
  • Rodriguez-Moran M Guerrero-Romero F Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial Diabetes Care 2003 26 4 1147 1152 12663588
  • Veronese N Watutantrige-Fernando S Luchini C Effect of magnesium supplementation on glucose metabolism in people with or at risk of diabetes: a systematic review and meta-analysis of double-blind randomized controlled trials Eur J Clin Nutr 2016 70 12 1463 27924111
  • Nadler JL Malayan S Luong H Shaw S Natarajan RD Rude RK Intracellular free magnesium deficiency plays a key role in increased platelet reactivity in type II diabetes mellitus Diabetes Care 1992 15 7 835 841 1516501
  • Nadler JL Buchanan T Natarajan R Antonipillai I Bergman R Rude R Magnesium deficiency produces insulin resistance and increased thromboxane synthesis Hypertension 1993 21 6 Pt 2 1024 1029 8505087
  • Gommers LM Hoenderop JG Bindels RJ de Baaij JH Hypomagnesemia in Type 2 Diabetes: A Vicious Circle? Diabetes 2016 65 1 3 13 26696633
  • Song Y He K Levitan EB Manson JE Liu S Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials Diabet Med 2006 23 10 1050 1056 16978367
  • Elin RJ Status of the determination of magnesium in mononuclear blood cells in humans Magnesium 1988 7 5–6 300 305 3075246
  • Huang CL Kuo E Mechanism of hypokalemia in magnesium deficiency J Am Soc Nephrol 2007 18 10 2649 2652 17804670
  • Whang R Welt LG Observations in experimental magnesium depletion J Clin Invest 1963 42 305 313 13976753
  • Guerrero-Romero F Simental-Mendia LE Hernandez-Ronquillo G Rodriguez-Morán M Oral magnesium supplementation improves glycaemic status in subjects with prediabetes and hypomagnesaemia: a double-blind placebo-controlled randomized trial Diabetes Metab 2015 41 3 202 207 25937055
  • Guerrero-Romero F Bermudez-Pena C Rodriguez-Moran M Severe hypomagnesemia and low-grade inflammation in metabolic syndrome Magnes Res 2011 24 2 45 53 21609903
  • Pearson TA Mensah GA Alexander RW Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 2003 107 3 499 511 12551878
  • Ridker PM Clinical application of C-reactive protein for cardiovascular disease detection and prevention Circulation 2003 107 3 363 369 12551853
  • Sukegawa H Maekawa Y Yuasa S Intensive statin therapy stabilizes C-reactive protein, but not chemokine in stable coronary artery disease treated with an everolimus-eluting stent Coron Artery Dis 2016 27 5 405 411 27105046
  • Mora S Ridker PM Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) – can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 2006 97 2A 33A 41A
  • Haendeler J Hoffmann J Zeiher AM Dimmeler S Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins Circulation 2004 110 7 856 861 15289372
  • Davignon J Jacob RF Mason RP The antioxidant effects of statins Coron Artery Dis 2004 15 5 251 258 15238821
  • Davi G Ciabattoni G Consoli A In vivo formation of 8-isoprostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation Circulation 1999 99 2 224 229 9892587
  • Kaviarasan S Muniandy S Qvist R Ismail IS F(2)-isoprostanes as novel biomarkers for type 2 diabetes: a review J Clin Biochem Nutr 2009 45 1 1 8 19590700
  • van ’t Erve TJ Kadiiska MB London SJ Mason RP Classifying oxidative stress by F2-isoprostane levels across human diseases: a meta-analysis Redox Biol 2017 12 582 599 28391180
  • Mak IT Chmielinska JJ Kramer JH Loss of neutral endopeptidase activity contributes to neutrophil activation and cardiac dysfunction during chronic hypomagnesemia: protection by substance P receptor blockade Exp Clin Cardiol 2011 16 4 121 124 22131854
  • Mak IT Kramer JH Chmielinska JJ Spurney CF Weglicki WB EGFR-TKI, erlotinib, causes hypomagnesemia, oxidative stress, and cardiac dysfunction: attenuation by NK-1 receptor blockade J Cardiovasc Pharmacol 2015 65 1 54 61 25343568
  • Mak IT Kramer JH Chen X Chmielinska JJ Spurney CF Weglicki WB Mg supplementation attenuates ritonavir-induced hyperlipidemia, oxidative stress, and cardiac dysfunction in rats Am J Physiol Regul Integr Comp Physiol 2013 305 10 R1102 R1111 24049113
  • Casoinic F Sampelean D Buzoianu AD Hancu N Baston D Serum Levels of oxidative stress markers in patients with type 2 diabetes mellitus and non-alcoholic steatohepatitis Rom J Intern Med 2016 54 4 228 236 28002036
  • Fadlelmawla A Al-Otaibi M Analysis of the water resources status in Kuwait J Water Resour Manage 2005 19 5 555 570
  • Al-Rashed MF Sherif MM Water resources in the GCC countries: an overview J Water Resour Manage 2000 14 1 59 75